Clinical Trial

Study of PRRT in Metastatic, WHO Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to learn about the feasibility and safety of using Peptide Receptor Radionuclide Therapy (PRRT) before and after surgical removal of a tumor. PRRT treatment is based on the administration of a radioactive product, 177-Lu DOTA-0-Tyr3-Octreotate (Lutathera®) and its use before and after surgery is thought to increase the overall survival benefit for patients with SSTR-positive gastroenteropancreatic neuroendocrine tumors GEP-NETs.
Protocol Amendment History 3 changes
critical Enrollment closed, study ongoing 2026-08-13
notable Primary completion pushed: 2026-07 -> 2026-11 2026-08-13
minor Completion moved earlier: 2027-09 -> 2027-05 2026-08-13
Trial Details
NCT Number NCT04609592
Lead Sponsor Stanford University
Collaborators: Novartis Pharmaceuticals
Conditions Gastroenteropancreatic Neuroendocrine Tumor
Enrollment 10 participants
Start Date 2021-03-17
Primary Completion 2026-11 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2026-08-12